Surface Oncology, Inc. (SURF)

NASDAQ: SURF · IEX Real-Time Price · USD
0.766
+0.005 (0.62%)
At close: Jun 2, 2023, 4:00 PM
0.786
+0.019 (2.53%)
After-hours: Jun 2, 2023, 6:29 PM EDT
0.62%
Market Cap 46.52M
Revenue (ttm) n/a
Net Income (ttm) -89.53M
Shares Out 60.72M
EPS (ttm) -1.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 100,173
Open 0.764
Previous Close 0.762
Day's Range 0.740 - 0.796
52-Week Range 0.555 - 2.150
Beta 1.68
Analysts Strong Buy
Price Target 4.50 (+487.31%)
Earnings Date Aug 2, 2023

About SURF

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibit... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 19, 2018
Employees 60
Stock Exchange NASDAQ
Ticker Symbol SURF
Full Company Profile

Financial Performance

In 2022, SURF's revenue was $30.00 million, an increase of 1016.49% compared to the previous year's $2.69 million. Losses were -$63.59 million, -18.98% less than in 2021.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for SURF stock is "Strong Buy." The 12-month stock price forecast is $4.5, which is an increase of 487.31% from the latest price.

Price Target
$4.5
(487.31% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2023

Updated clinical data from Phase 2 studies evaluating SRF388 in both liver and lung cancer expected in the second quarter of 2023

1 month ago - GlobeNewsWire

Surface Oncology Presents New Preclinical Data on SRF114, a fully human anti-CCR8 antibody, at the AACR Annual Meeting 2023

– New in vivo data show SRF114 promotes a pro-inflammatory tumor microenvironment resulting in robust antitumor activity in mouse models – – New in vivo data show SRF114 promotes a pro-inflammatory tu...

1 month ago - GlobeNewsWire

Surface Oncology to Present New Preclinical SRF114 Data at the American Association for Cancer Research (AACR) Annual Meeting 2023

CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenv...

2 months ago - GlobeNewsWire
}

Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2022

SRF388 clinical program advancing well; updated clinical data expected in the first half of 2023

3 months ago - GlobeNewsWire

Surface Oncology to Participate in the Cowen 43rd Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvi...

3 months ago - GlobeNewsWire

Surface Oncology to Participate in the 2023 Guggenheim Oncology Days Conference

CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvi...

4 months ago - GlobeNewsWire

Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors

SRF114 is designed to preferentially deplete CCR8 + Treg cells within the tumor microenvironment and has demonstrated highly specific CCR8-exclusive binding and reduced tumor growth in pre-clinical st...

5 months ago - GlobeNewsWire

Surface Oncology to Present Non-clinical Data for SRF388 and SRF114 at the Society for Immunotherapy of Cancer 2022 Annual Meeting

Data further support SRF388 and SRF114 clinical development programs Data further support SRF388 and SRF114 clinical development programs

7 months ago - GlobeNewsWire
}

Surface Oncology Announces Promising SRF388 Monotherapy Data in Non-Small Cell Lung Cancer (NSCLC), Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination Cohort

– Two confirmed partial responses to SFR388 monotherapy treatment in squamous NSCLC;  third patient with NSCLC experienced durable disease stabilization for over a year –

7 months ago - GlobeNewsWire

VIB and Surface Oncology Announce Publication in Cell Reports Revealing IL-27 Structure and the Mechanism of Action for SRF388

– Study reveals the structural basis of receptor activation and signaling by IL-27 cytokine – – Study elucidates how SRF388 binds to IL-27 to prevent interaction with the IL-27 receptor, inhibiting th...

8 months ago - GlobeNewsWire

Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting

- New preclinical data indicate IL-27 induces a gene expression signature  that has been associated with resistance to chemotherapy, radiotherapy, and checkpoint inhibition -

9 months ago - GlobeNewsWire

Surface Oncology to Participate in the Baird 2022 Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenv...

9 months ago - GlobeNewsWire

Surface Oncology to Participate in the Gilmartin Group Emerging Growth Company Showcase

CAMBRIDGE, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvi...

10 months ago - GlobeNewsWire
}

Surface Oncology Reports Financial Results and Business Highlights for Second Quarter 2022

– SRF388 clinical data presented at 2022 ASCO Annual Meeting demonstrated monotherapy responses in two different indications, combination activity and notable disease stabilization –

10 months ago - GlobeNewsWire

Surface Oncology to Participate in the 2022 Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvi...

10 months ago - GlobeNewsWire

Surface Oncology Appoints Carsten Brunn to Board of Directors

CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvi...

1 year ago - GlobeNewsWire

Surface Oncology Announces Publication of New Study Demonstrating the Role of the IL-27 Pathway in Hepatocellular Carcinoma

- Non-clinical findings further support the potential of SRF388 to treat patients suffering from liver cancer -

1 year ago - GlobeNewsWire

Surface Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor mic...

1 year ago - GlobeNewsWire

Surface Oncology to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvi...

1 year ago - GlobeNewsWire

Surface Oncology to Present New SRF388 Clinical Data at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

– SRF388 demonstrated clinical activity in multiple solid tumor types with three confirmed partial responses across NSCLC, RCC and HCC –

1 year ago - GlobeNewsWire

Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2022

– Cash runway extended into 2024 –

1 year ago - GlobeNewsWire

Surface Oncology to Present Clinical Update on SRF388 at American Society of Clinical Oncology Annual Meeting

CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenv...

1 year ago - GlobeNewsWire

Surface Oncology Named one of the 2022 Best Places to Work by Boston Business Journal

CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenv...

1 year ago - GlobeNewsWire

Surface Oncology Announces Initiation of Phase 2 Studies Evaluating SRF388 in Patients with Hepatocellular Carcinoma and Non-Small-Cell Lung Cancer

Randomized Phase 2 clinical study evaluating SRF388 in first-line hepatocellular carcinoma in clinical collaboration with Roche

1 year ago - GlobeNewsWire

Surface Oncology Presents New SRF388 Data at the American Association for Cancer Research (AACR) Annual Meeting 2022

Poster presentation highlights translational work supporting recommended dosing for SRF388 Phase 2 trials Poster presentation highlights translational work supporting recommended dosing for SRF388 Pha...

1 year ago - GlobeNewsWire